Nanjing Leads Biolabs
Clinical trials sponsored by Nanjing Leads Biolabs, explained in plain language.
Nanjing Leads Biolabs is a biopharmaceutical company focused on developing antibody drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for hard-to-treat myeloma: experimental drug LBL-034 enters human trials Results expected Oct 2026 (estimated)
- New hope for advanced cancer: LBL-024 trial now recruiting Results expected Dec 2026 (estimated)
- New drug cocktail shows promise against tough cancers Results expected Dec 2026 (estimated)
- New drug cocktail aims to shrink Hard-to-Treat neuroendocrine tumors Results expected Dec 2026 (estimated)
-
Can a new drug combo shrink metastatic colorectal tumors?
Disease control Not yet recruitingThis trial tests whether an experimental drug called LBL-024, when combined with standard treatments like bevacizumab, oxaliplatin, capecitabine, or fruquintinib, can safely shrink tumors in people with metastatic colorectal cancer. The study includes adults aged 18 to 75 who hav…
Phase 1/2 • Sponsor: Nanjing Leads Biolabs Co.,Ltd • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a new drug boost chemotherapy for a rare cancer?
Disease control Not yet recruitingThis phase III trial is testing whether adding an experimental drug called LBL-024 to standard chemotherapy can help people with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC), a rare and aggressive cancer. Participants will receive either LBL-024 or a placebo alongsid…
Phase 3 • Sponsor: Nanjing Leads Biolabs Co.,Ltd • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC